Kornimate/medical-research-clean huggingface dataset:
indirect evaluation of lithium level in blood using non-invasive sweat biosensors

Conditions: Lithium Level Detection in Sweat

Summary: indirect evaluation of the accuracy and the efficacy of biosensors developed for li+ detection in sweat.

lithium (li+) is one of the most widely used and studied medications for treating of bipolar mood disorder, resistant cases of major psychiatric disorders and especially major depressive disorder. after administration, more than 95% of administered dose of li+ is eliminated unchanged in the urine, less than 5% - in the saliva, sweat, and feces. up to 40% of patients that are on li+ therapy encounter adverse effects that can be explained by drug involvement in various biochemical processes. li+ efficacy and side effect manifestation are obviously determined by the drug concentration in blood. the optimal way to prevent manifestation of side effects is to control that li+ serum level is within therapeutic range. a blood test is often ordered to monitor the serum level of li+ to ensure target serum levels are reached. the available methods for blood li+ are invasive, time consuming, and cause of discomfort for patients, yet are of a great importance as levels of drug in blood outside the therapeutic range may dramatically affect patient health. it is especially of importance for li+ treatments it has a narrow therapeutic window - 0.6-1.5 mmol/l. thus, there is a growing need for a reliable, comfortable, and inexpensive method for detection of li+ in blood that can be performed easily in an in-patient setting and automatically whenever necessary without the need for a clinic visit out-patient setting. spectrophon ltd has developed an algorithm that allows calculation of levels of various compounds contained in sweat using standard ppg sensors with special coating and thus to estimate the levels of corresponding chemicals in the bloodstream. this algorithm has proven useful and accurate in clinical trials on detection of dehydration level, blood sodium level, and blood glucose level. we suggest that spectrophon biosensors can be used to detect the levels of li+ in sweat that will allow non-invasive estimation of the level of corresponding medication in blood in real-time.

Eligibility criteria:
inclusion criteria: * meeting diagnostic and statistical manual 5th edition (dsm-v) criteria for mdd, bmd, schizoaffective disorder, schizophrenia; * patients must be on constant li+ treatment or prior their first drug administration. * ability and willingness to sign an informed consent form for participation in the study. exclusion criteria: * evidence of serious disorder; * unstable chronic disease; * kidney disease * pregnancy; * contraindication for li+ treatment.

Keywords: lithium biosensor sweat major depressive disorder schizoaffective disorder bipolar mood disorder schizophrenia
shoulder muscle imbalance as a risk factor for shoulder injury in elite badminton players

Conditions: Sport Injury; Shoulder Injuries

Summary: background: to assess the impact of pre-season clinical measures and rotator muscles strength on the risk of significant shoulder injury (ssi) in elite badminton players design: prospective cohort study participants: nineteen elite adolescents badminton players were included and followed over the badminton season (from september 2018 to may 2019 and/or from september 2019 to may 2020) . independent variables: a pre-season visit consisted in clinical and isokinetic shoulder strength testing. clinical testing consisted in the shoulder range of motion (rom) measurements and the table-to-acromion distance (tad)isokinetic internal and external rotator shoulder muscles strength was tested at 60 and 240°/s. conventional and functional (eccentric-to-concentric) ratios (fr) were calculated. ssi collection was performed by an experienced sport physician.


Eligibility criteria:
inclusion criteria: all the elite badminton players from a high-level club and the national institute of sport, expertise, and performance exclusion criteria: players who had ssi in the 3 months prior to the isokinetic test or had shoulder surgery
clinically relevant pancreatic fistula after pancreaticoduodenectomy

Conditions: Pancreatic Fistula

Summary: patients who are diagnosed with periampullary cancer will be performed pancreaticoduodenectomy with 3 types of pancreatic-jejunal anastomosis reconstructions. the investigator will analysis the complication of pancreatic fistula about: the clinical symptoms, laboratory test changing, intra-operative morphology, the risk factors

this study will conduct at two centers at the same time: university of medicine and pharmacy center and cho ray hospital. the patients will be consulted to participate to this research from september, 2021 to april, 2023. plan for conducting study: * the investigator consults and gets consensus form of the patient with periampullary cancer. * the patient will be prepared for pancreaticoduodenectomy: pre-operative laboratory test, pre-operative biliary drainage, anesthetic checking. * the investigator collected intr-operative data, include type of pancreatic-duodenal reconstruction, type of pancreatic duct's drainage, quantity of blood loss and blood transfusion. * the investor follows post-operative period. * if there are pancreatic fistula appear, the investigator will collect the clinical signs, laboratory test changing, re-operative morphology. * the investigator analysis the risk factors of pancreatic fistula. data analysis: * to determine the incidence of pancreatic fistula, the morphology of pancreatic fistula, descriptive statistics will be used. * to determine the risk factors of pancreatic fistula, logistic regression will be used. sample size: * the investigator plans to collect 145 patients in the research period. plan for missing data: * any case that miss information will be removed from the study.

Eligibility criteria:
inclusion criteria: * patient with periampullary cancer and can be performed pancreaticoduodenectomy. * pancreaticoduodenectomy with one of three types of pancreatic - duodenal anastomosis reconstructions. exclusion criteria: * the patient does not consent to participate in the study

Keywords: risk factor
c-reactive protein levels in acute apical abscess due to root canal infection

Conditions: Dentoalveolar Abscess

Summary: c-reactive protein levels of patients with acute apical abscess are evaluated before and after root canal treatment

in patients with acute apical abscess c-reactive proteins are evaluated before and after root canal treatment. in this intra-canal medications calcium hydroxide and triple antibiotic paste are compared. pai score of the corresponding tooth is noted .

Eligibility criteria:
inclusion criteria: patient with acute apical abscess exclusion criteria: * teeth with evidence of previous initiated root canal treatment * history of myocardial infarction, coronary heart disease * patients allergic to local anesthetic * patients under steroid medication * patients who are immunocompromised
structural imaging assisted retinal fluorescence lifetime imager (starfli)

Conditions: Retinal Disease

Summary: to investigate the feasibility of a combined oct/flim device

to investigate the feasibility of a combined optical coherence tomography/ fluorescence lifetime measurement (oct/flim) device.

Eligibility criteria:
inclusion criteria: * subject must be willing to give written informed consent * age: patients and probands 18 years or greater * both eyes will be assessed in the study exclusion criteria: * patients not willing or able to sign informed consent * patients younger than 18 years * patients with epilepsy
the ladies acute coronary syndromes study

Conditions: Acute Coronary Syndromes; Menopause

Summary: the ladies acs study will investigate the relation between age at menopause and severity of coronary artery disease in menopausal women with acute coronary syndromes and clinical indication to coronary angiography.

multicenter prospective study in consecutive patients hospitalized with a wide spectrum of acs and clinical indication to coronary angiography. consecutive patients older than 55 years with an acs undergoing coronary angiography are eligible for the study, irrespective of subsequent revascularization. eligible are women and men with a 2:1 enrolment ratio. patients will be stratified according to gender and age, including four age categories: 55-64, 65-74, 75-85 and \>85 years. each age category will include 200 patients, and enrolment in each category will be stopped once this number has been reached. a specific electronic web-based crf will collect clinical and procedural data. clinical data input will take place at the participating centers. angiographic data input will be performed at rthe angiographic corelab, blinded of clinical data. the e-crf will collect data on * the characteristics of the acs * the relevant risk factors for cad and known prognostically relevant variables * prior clinical history (prior mi, pci, cabg, heart failure, stroke) * in women fertility history will be captured by specific items, including age at first and last menstrual period, past use of oral contraceptives, ongoing and past hormone replacement therapy (hrt) and whether they had undergone a hysterectomy and/or oophorectomy, as well as information on the number of full-term pregnancies (the sum of live births and stillbirths). age at menarche is defined as the age at the first menstrual period. reproductive life span is automatically calculated calculated by subtracting the age at menarche from the age at menopause. the presence of hot flushes, their severity and duration in years will be also captured. the extent of coronary artery disease will be evaluated at a central corelab using the gensini score and the syntax score

Eligibility criteria:
inclusion criteria: patients \>55 years of age with all of the following characteristics: * symptoms suggestive of acute myocardial ischemia within the previous 48 hours. * the diagnosis of an acs must be confirmed by a typical rise and fall in serum troponin levels as defined by the third universal definition of myocardial infarction. * ecg signs of myocardial ischemia defined as either transient or persistent st segment elevation or depression \>0.5 mm (but \>1 mm in the case of st-segment elevation), or persistent and definite t-wave inversion \>1 mm, including the pseudonormalization of a previously negative t-wave, in ≥2 contiguous leads. exclusion criteria: * none

Keywords: acute coronary syndrome, coronary arteriography, menopause
danish prostate cancer consortium study-1

Conditions: Prostate Cancer

Summary: the purpose of the study is to investigate if a new promising microrna-based urine biomarker test for prostate cancer, called ucap, is better than the current standard test (psa) to identify men who would benefit from an mri scan of the prostate. the study will include 2,500 men referred to mri of the prostate at three major hospital centers in denmark (aarhus, odense, and herlev) and compare the accuracy of ucap to psa. based on preliminary data it is expected that ucap will be \>20% better than psa at identifying treatment-requiring cancer. hence, ucap could help to better pre-select men for mri and thereby reduce unnecessary mri scans, unnecessary prostate biopsies, as well as overdiagnosis and overtreatment of indolent pcs, while maintaining high sensitivity for aggressive pc that needs early detection and early treatment.


Eligibility criteria:
inclusion criteria: * age ≥ 18 years. * understand oral and written danish. * referred to mri (multi or bi-parametric) due to suspicion of pc at auh, ouh, or hgh. exclusion criteria: * previously diagnosed with pc or other urogenital cancers. * has one or more contraindications for mri. * have had gender reassignment treatment. * blood psa levels \> 20 μg/l.
the effect of ozone therapy for lumbar herniated disc

Conditions: Lumbar Herniated Disc

Summary: the purpose of this study is to assess the efficacy (vs. placebo) of ozone infiltration and its effectiveness in comparison with micro discectomy in the treatment of lumbar herniated disc with criteria for surgery.


Eligibility criteria:
inclusion criteria: * diagnosis of herniated disc by surgeons from participating hospitals * sciatic pain of 5 or more on visual analogue scale * pain radiated to appropriate area according to herniated disc * on waiting list for disc surgery at one of participating hospitals exclusion criteria: * inability to fill out questionnaires (vas, roland morris, sf12) * calcified or migrated herniated disc * herniated disc with indications for laminectomy or arthrodesis * clinically relevant partial paralysis * simultaneous cervical and dorsal symptomatic herniated discs * previous lumbar spine surgery * presence of other spinal pathology * significant glucose-6-phosphate-dehydrogenase deficit * allergy to ozone * treatment with oral anticoagulants

Keywords: disc herniation lumbar ozone therapy
biomarkers in samples from patients with down syndrome and acute megakaryoblastic leukemia

Conditions: Leukemia

Summary: rationale: studying samples of blood or tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in dna and identify biomarkers related to cancer. purpose: this research study is studying biomarkers in samples from patients with down syndrome and acute megakaryoblastic leukemia.

objectives: * determine whether megakaryocyte differentiation agents comprising a rho kinase inhibitor and a jak3 inhibitor can lead to proliferation arrest, polyploidization, and terminal differentiation of blasts in specimens from patients with down syndrome and acute megakaryoblastic leukemia. outline: cryopreserved specimens are cultured and treated in vivo (in mice) and in vitro with megakaryocytic differentiation agents comprising a rho kinase inhibitor and a jak3 inhibitor.

Eligibility criteria:
disease characteristics: * diagnosis of acute megakaryoblastic leukemia * diagnosis of down syndrome * cryopreserved specimens available patient characteristics: * not specified prior concurrent therapy: * not specified

Keywords: adult acute megakaryoblastic leukemia (m7) childhood acute megakaryocytic leukemia (m7) recurrent adult acute myeloid leukemia recurrent childhood acute myeloid leukemia untreated adult acute myeloid leukemia untreated childhood acute myeloid leukemia and other myeloid malignancies
impact of varying doses of prucalopride on improving gut function recovery after elective colorectal surgery

Conditions: Post-Op Complication

Summary: postoperative ileus (poi) is a common complication after abdominal surgery, causing symptoms like nausea, vomiting, abdominal distension, and delayed passage of flatus and stool. management remains challenging, with limited pharmacological options available. prucalopride, a selective serotonin 5-ht4 receptor agonist, has shown promise in accelerating gastrointestinal recovery after surgery. however, the optimal timing and dosing for preventing poi remains unclear. higher doses may provide more potent prokinetic effects in the postoperative setting. his study investigates if higher doses of prucalopride (4 mg) improve bowel function return and hospital stay in elective colorectal surgery patients compared to standard doses and placebo.

postoperative ileus (poi) is a common complication after abdominal surgery, particularly colorectal procedures, which can delay recovery and prolong hospital stay. poi is characterized by a transient cessation of coordinated bowel motility, leading to symptoms such as nausea, vomiting, abdominal distension, and delayed passage of flatus and stool. effective management of poi remains challenging, with limited pharmacological options available. prucalopride, a highly selective serotonin 5-ht4 receptor agonist, has shown promise in accelerating gastrointestinal recovery after surgery. however, the optimal timing and dosing of prucalopride for preventing poi remains unclear. studies have shown dose-dependent improvements in outcomes with doses up to 4 mg daily. higher doses may provide more potent prokinetic effects in the postoperative setting, but no studies have examined doses above 2 mg for prevention of poi in colorectal surgery. the purpose of this study is to determine if higher doses of prucalopride (4 mg) result in faster return of bowel function and shorter hospital stay compared to the standard dose (2 mg) and placebo in patients undergoing elective colorectal surgery.

Eligibility criteria:
inclusion criteria: * undergoing elective colorectal surgery, including but not limited to colectomy, rectal resection, and sigmoid resection. exclusion criteria: * emergency surgery * total colectomy * creation of a stoma * pre-existing gastrointestinal disorders * severe renal or hepatic impairment * known hypersensitivity to prucalopride.

Keywords: pro kinetic gut function recovery
study of efficacy and safety of drugs bcd-033 and rebif for treatment of patients with multiple sclerosis

Conditions: Multiple Sclerosis

Summary: study design is double-blind, randomized, placebo-controlled study in 3 parallel groups with the use of active comparator and placebo. total duration of therapy of about 2 years. study hypothesis is equivalence of efficacy and safety of the investigational drug bcd-033 original drug rebif®.


Eligibility criteria:
inclusion criteria: 1. age 18-55 2. patients of both genders with multiple sclerosis (mcdonald criteria 2010) 3. no relapses 28 days before randomisation 4. expanded disability status scale score 0-5,5 exclusion criteria 1. primary or secondary progression of multiple sclerosis 2. expanded disability status scale score more then 5,5 3. severe depression, suicide ideas and/or attempts 4. systemic corticosteroid application in 30 days before randomisation
trial of the effectiveness of aq/as, sp/aq and sp/cq for uncomplicated malaria in gambian children

Conditions: Malaria

Summary: the purpose of this trial is to compare the effectiveness of three combination treatments for uncomplicated malaria when given in operational settings, without supervision of doses other than the first dose.

children aged 0.5-10 years presenting at health centres with fever or history of fever and other symptoms suggestive of malaria will be screened; children found to have uncomplicated plasmodium falciparum malaria will be randomized to receive treatment with as/aq, sp/aq or sp/cq. a drug dispenser will supervise the first dose of medication and subsequent doses will be given to the child's parent to be administered at home, unsupervised by the study team. patients will be visited at home three days later. unused medication will be counted and the mother will be asked about the number of doses the child received and any side effects. children will be seen again 2 and 4 weeks after treatment to collect finger prick samples for packed cell volume (pcv) and malaria microscopy. the primary endpoint is clinical failure by day 28. analysis will be by intention to treat.

Eligibility criteria:
inclusion criteria: * presentation at health centre with febrile illness * monoinfection with p. falciparum * parasitaemia \>=500/microlitre * fever or history of fever exclusion criteria: * signs of severe or complicated malaria (persistent vomiting with or without dehydration, history of convulsion during the present illness, inability to sit or stand, parasitaemia \>200,000/ul) * severe malnutrition * clinically evident concomitant disease * pcv \<20% * history of allergy to the study medications * residence outside the study area and hence difficult to follow up

Keywords: malaria treatment artemisinin based combination therapy plasmodium falciparum pragmatic trial effectiveness
clinical trial on alzheimer disease, presbycusis and hearing aids

Conditions: Alzheimer Disease; Presbycusis

Summary: this is a 12-months' randomized clinical trial that aims at studying the benefit of bilateral hearing aids in hearing impaired patients suffering from a slight to moderate stage alzheimer disease. the benefit of this intervention will be studied in the cognitive, behavioural, quality of life and economic fields. 2groups are involved in this trial: intervention group: 12 months' treatment with active hearing aids, fitted hearing impairment control group: 6 months' treatment with placebo hearing aids, followed with 6 months' active hearing aids, fitted hearing impairment


Eligibility criteria:
inclusion criteria: * \> 65 year-old * medical diagnosis of alzheimer disease * 15 ≤ mmse ≤ 25 * no hearing aids in the last 2 years * motivated caregiver living with the patient * sensorineural hearing loss exclusion criteria: * beginning of an anticholinesterasic treatment in the last 6 months * change in the anticholinesterasic treatment in the last 2 months

Keywords: alzheimer disease cognitive impairment sensorineural hearing loss hearing aids
prophylactic use of levosimendan versus milrinone in open heart surgery in infants

Conditions: Low Cardiac Output Syndrome

Summary: pediatric patients, especially infants undergoing open heart surgery have a predictable fall in cardiac index 6 to 18 hours after surgery, the so-called low cardiac output syndrome (lcos). patients, who have lcos require more monitoring, more medication and a longer stay in intensive care unit. to prevent lcos the phosphodiesterase inhibitor milrinone is routinely used during the first 24 hours after surgery. levosimendan, a calcium- sensitizer improves cardiac muscle contractile force, vascular smooth muscle relaxation and coronary blood flow through calcium sensitization of the myocardial contractile filaments and opening of potassium channels without increasing oxygen consumption of the heart muscle cells. as the myocardium of infants is more calcium dependent than in later life, levosimendan should be of special benefit in this age group. the purpose of this study is to investigate whether levosimendan is superior to milrinone in preventing lcos in infants after corrective open heart surgery.


Eligibility criteria:
inclusion criteria: * age younger than one year * corrective open heart surgery with biventricular repair, except tetralogy of fallot exclusion criteria: * missing written consent of parents * weight less than 3 kg * preoperative lcos * gestational age less than 36 weeks * preexisting renal failure * preexisting thrombopenia * preoperative cardiopulmonary resuscitation * preoperative use of milrinone or levosimendan

Keywords: low cardiac output syndrome open heart surgery infants low cardiac output syndrome in infants undergoing corrective open heart surgery